Skip to main content

Dr. Lyndsay J. Willmott, MD

Gynecologic Oncology (Gynecologic Oncology Physician)

2222 E Highland Ave, Suite 400
Phoenix, AZ 85016

Who else practices at this address →

Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas

Call (602) 277-4868

  • Medicare participating

At a glance

Years since graduation
23
In the NPI registry since
2006
Medicare patients seen, 2024
180

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2003Medical school: State University of New York at Buffalo School of Medicine
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Gynecologic Oncology Physician primary
    AZ license 46677
  • Obstetrics & Gynecology Physician
    AZ license 46677

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Gynecologic Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
180
Services billed
424
Patients’ average age
72
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes9168
Established patient office or other outpatient visit, 40-54 minutes8548
Established patient office or other outpatient visit, 20-29 minutes8060
New patient office or other outpatient visit, 60-74 minutes3737
Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less1616

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 23 companies reported 102 payments worth $64,899 in total to this clinician.

By type
Compensation for services other than consulting (speaking, faculty)$37,786
Consulting Fee$20,277
Travel and Lodging$4,319
Food and Beverage$2,517

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Dec 11, 2025AstraZeneca Pharmaceuticals LP
Dec 11, 2025
Consulting Fee
LYNPARZA · Oncology
$6,700
Jul 16, 2025GlaxoSmithKline, LLC.
Jul 16, 2025
Compensation for services other than consulting (speaking, faculty)
JEMPERLI · ONCOLOGY
$5,800
May 2, 2025Merck Sharp & Dohme LLC
May 2, 2025
Compensation for services other than consulting (speaking, faculty)
KEYTRUDA · ONCOLOGY
$5,760
May 30, 2025Merck Sharp & Dohme LLC
May 30, 2025
Compensation for services other than consulting (speaking, faculty)
KEYTRUDA · ONCOLOGY
$5,760
Aug 27, 2025AbbVie Inc.
Aug 27, 2025
Compensation for services other than consulting (speaking, faculty)
ELAHERE · ONCOLOGY
$4,725
Nov 17, 2025GlaxoSmithKline, LLC.
Nov 17, 2025
Compensation for services other than consulting (speaking, faculty)
JEMPERLI · ONCOLOGY
$4,350
Aug 26, 2025Genmab U.S., Inc.
Aug 26, 2025
Compensation for services other than consulting (speaking, faculty)
Tivdak · Oncology
$3,275
May 2, 2025AbbVie Inc.
May 2, 2025
Compensation for services other than consulting (speaking, faculty)
ELAHERE · ONCOLOGY
$3,038
Dec 4, 2025GlaxoSmithKline, LLC.
Dec 4, 2025
Compensation for services other than consulting (speaking, faculty)
JEMPERLI · ONCOLOGY
$2,900
Nov 10, 2025AbbVie Inc.
Nov 10, 2025
Consulting Fee
ELAHERE · ONCOLOGY
$2,700
All 30 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 23, 2025Daiichi Sankyo Inc.
Dec 23, 2025
Consulting Fee$1,166
Dec 16, 2025GlaxoSmithKline, LLC.
Dec 16, 2025
Travel and Lodging
JEMPERLI · ONCOLOGY · travel to Green Valley, AZ · in-kind
$100
Dec 11, 2025AstraZeneca Pharmaceuticals LP
Dec 11, 2025
Consulting Fee
LYNPARZA · Oncology
$6,700
Dec 9, 2025Pfizer Inc.
Dec 9, 2025
Consulting Fee
TIVDAK · ONCOLOGY
$1,440
Dec 9, 2025Pfizer Inc.
Dec 9, 2025
Consulting Fee
TIVDAK · ONCOLOGY
$720
Dec 4, 2025GlaxoSmithKline, LLC.
Dec 4, 2025
Compensation for services other than consulting (speaking, faculty)
JEMPERLI · ONCOLOGY
$2,900
Nov 17, 2025GlaxoSmithKline, LLC.
Nov 17, 2025
Compensation for services other than consulting (speaking, faculty)
JEMPERLI · ONCOLOGY
$4,350
Nov 10, 2025AbbVie Inc.
Nov 10, 2025
Consulting Fee
ELAHERE · ONCOLOGY
$2,700
Nov 4, 2025GlaxoSmithKline, LLC.
Nov 4, 2025
Travel and Lodging
JEMPERLI · ONCOLOGY · travel to Tucson, AZ · in-kind
$1,133
Oct 10, 2025GlaxoSmithKline, LLC.
Oct 10, 2025
Consulting Fee
ZEJULA · ONCOLOGY
$2,175
Oct 2, 2025GlaxoSmithKline, LLC.
Oct 2, 2025
Compensation for services other than consulting (speaking, faculty)
ZEJULA · ONCOLOGY
$1,089
Sep 12, 2025AbbVie Inc.
Sep 12, 2025
Travel and Lodging
ELAHERE · ONCOLOGY · travel to DENVER, CO · in-kind
$358
Aug 27, 2025AbbVie Inc.
Aug 27, 2025
Compensation for services other than consulting (speaking, faculty)
ELAHERE · ONCOLOGY
$4,725
Aug 27, 2025AbbVie Inc.
Aug 27, 2025
Travel and Lodging
ELAHERE · ONCOLOGY · travel to TUCSON, AZ · in-kind
$830
Aug 26, 2025Genmab U.S., Inc.
Aug 26, 2025
Compensation for services other than consulting (speaking, faculty)
Tivdak · Oncology
$3,275
Jul 25, 2025Genmab U.S., Inc.
Jul 25, 2025
Consulting Fee
Epkinly · Oncology · in-kind
$1,458
Jul 21, 2025Merck Sharp & Dohme LLC
Jul 21, 2025
Consulting Fee
ONCOLOGY
Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement.
$915
Jul 16, 2025GlaxoSmithKline, LLC.
Jul 16, 2025
Compensation for services other than consulting (speaking, faculty)
JEMPERLI · ONCOLOGY
$5,800
May 30, 2025Merck Sharp & Dohme LLC
May 30, 2025
Compensation for services other than consulting (speaking, faculty)
KEYTRUDA · ONCOLOGY
$5,760
May 30, 2025Merck Sharp & Dohme LLC
May 30, 2025
Travel and Lodging
KEYTRUDA · ONCOLOGY · travel to Honolulu, HI
$150
May 2, 2025Merck Sharp & Dohme LLC
May 2, 2025
Compensation for services other than consulting (speaking, faculty)
KEYTRUDA · ONCOLOGY
$5,760
May 2, 2025AbbVie Inc.
May 2, 2025
Compensation for services other than consulting (speaking, faculty)
ELAHERE · ONCOLOGY
$3,038
May 2, 2025Merck Sharp & Dohme LLC
May 2, 2025
Travel and Lodging
KEYTRUDA · ONCOLOGY · travel to ALBUQUERQUE, NM
$150
Apr 22, 2025Merck Sharp & Dohme LLC
Apr 22, 2025
Travel and Lodging
KEYTRUDA · ONCOLOGY · travel to ALBUQUERQUE, NM · in-kind
$500
Apr 22, 2025Merck Sharp & Dohme LLC
Apr 22, 2025
Travel and Lodging
KEYTRUDA · ONCOLOGY · travel to ALBUQUERQUE, NM · in-kind
$239
Apr 11, 2025AbbVie Inc.
Apr 11, 2025
Travel and Lodging
ELAHERE · ONCOLOGY · travel to DALLAS, TX · in-kind
$555
Apr 11, 2025AbbVie Inc.
Apr 11, 2025
Travel and Lodging
ELAHERE · ONCOLOGY · travel to DALLAS, TX · in-kind
$304
Mar 27, 2025GlaxoSmithKline, LLC.
Mar 27, 2025
Consulting Fee
JEMPERLI · ONCOLOGY
$1,450
Mar 27, 2025GlaxoSmithKline, LLC.
Mar 27, 2025
Compensation for services other than consulting (speaking, faculty)
JEMPERLI · ONCOLOGY
$1,089
Mar 12, 2025Daiichi Sankyo Inc.
Mar 12, 2025
Consulting Fee$1,554

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Arizona →

Industry-funded research

Named as a principal investigator on 13 industry-funded studies in 2025, from 8 companies. The companies reported $1,913,828 in research payments for these studies, mostly to the institutions running them.

  • Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors
    Genmab U.S., Inc.
  • A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician s Choice in Participants With Endometrial Cancer Who Have…
    Merck Sharp & Dohme LLC
  • A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient dMMR Advanced or Recurrent Endometrial Ca…
    Merck Sharp & Dohme LLC
  • A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer KEYNOTE-B96 , ENGOT…
    Merck Sharp & Dohme LLC
  • A phase third,randomized,double blind,placebo controlled,multi centre,global study of volrustomig in women with high risk locally advanced cervical cancer who have not progressed following platinum based,concurrent ch…
    AstraZeneca Pharmaceuticals LP
  • A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After …
    Merck Sharp & Dohme LLC
  • A phase iii multicenter randomized placebo controlled study of atezolizumab versus placebo in com
    Genentech, Inc.
  • A randomized, double-blind, phase 3 comparison of platinum-based thera
    GlaxoSmithKline, LLC.
  • Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
    Aadi Bioscience, Inc. · Completed · NCT05103358
  • A Phase III randomized study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib in patients with no germline BRCA mutation detected, platinum-resistant or refractory, high grade serou…
    Novartis Pharmaceuticals Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Gynecologic Oncology clinicians in Phoenix

Sources

NPI registry (CMS NPPES, November 2026; record last updated March 8, 2018), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1043229529. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.